基因多态性作为惰性非霍奇金淋巴瘤和套细胞淋巴瘤患者接受苯达莫司汀联合利妥昔单抗治疗疗效与毒性预测因子的研究
研究纳入70例接受利妥昔单抗375 mg/m2联合苯达莫司汀90 mg/m2每28天方案的惰性非霍奇金淋巴瘤和套细胞淋巴瘤患者,总体缓解率97.1%(完全缓解率73.9%),中位随访24个月未发现所分析的单核苷酸多态性与完全缓解率及无进展生存期相关,但IL2(rs2069762)多态性与皮疹发生相关(P=0.0001)。
要点
- 总体缓解率97.1%,完全缓解率73.9%,3-4级中性粒细胞减少24/70例。
- 中位随访24个月,所分析的单核苷酸多态性与完全缓解率及无进展生存期均未发现相关性。
- IL2(rs2069762)多态性与皮疹发生相关(P=0.0001)。
核心结论
- 研究提示细胞因子单核苷酸多态性可能在苯达莫司汀相关毒性中起作用,可能是一个有前景的研究领域。
研究设计与样本
- 研究对70例接受利妥昔单抗375 mg/m2联合苯达莫司汀90 mg/m2每28天方案(一线及≥二线治疗)的惰性非霍奇金淋巴瘤和套细胞淋巴瘤患者样本进行基因分型。
主要发现
- 总体缓解率97.1%(完全缓解率73.9%)。
- 治疗毒性包括3-4级中性粒细胞减少24/70例、感染21/70例(其中3级1/70例)、皮疹26/70例(其中3级2/70例)。
- 中位随访24个月,所分析的单核苷酸多态性与完全缓解率及无进展生存期均未发现相关性。
- IL2(rs2069762)单核苷酸多态性与皮疹发生相关(P=0.0001)。
关键数值与推荐
- 检测的单核苷酸多态性包括IL2(rs2069762)、IL10(rs1800890、rs10494879)、VEGFA(rs3025039)、IL8(rs4073)、CFH(rs1065489)和MTHFR(rs1801131)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bendamustine is used in combination with rituximab (BR) to treat indolent non-Hodgkin lymphomas (iNHL) and mantle cell lymphoma (MCL). The variability in treatment efficacy and toxicity could be related to single nucleotide polymorphisms (SNPs) in immune response genes. We would like to show a correlation between SNPs and treatment outcome in iNHL and MCL patients receiving BR. We investigated some SNPs that had already been associated with NHL outcome. Samples were genotyped for the IL2 (rs2069762), IL10 (rs1800890, rs10494879), VEGFA (rs3025039), IL8 (rs4073), CFH (rs1065489) and MTHFR (rs1801131) SNPs by allelic discrimination assays. We enrolled 70 patients that received rituximab 375 mg/m2 and bendamustine 90 mg/m2 every 28 days, both as first-line treatment and ≥ second-line regimens. Overall response rate was 97·1% (complete response [CR] rate 73·9%). Treatment toxicity included grade 3-4 neutropenia (24/70 patients), infections (21/70 patients; 1/70 grade 3), skin rash (26/70 patients; 2/70 grade 3). After a median follow-up of 24 months we did find any correlation between the analysed SNPs, CR rate and PFS. However, we demonstrated an association between the SNP in IL2 (rs2069762) and the onset of skin rash (P = 0·0001). Our study suggests a role for cytokine SNPs in bendamustine-related toxicity, which could represent a promising research field.
引用
- Cencini E, Sicuranza A, Fabbri A, et al. Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab. Br J Haematol. 2018. PMID: 30203425. doi:10.1111/bjh.15582
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。